TokenPost·
Tandem Diabetes Care Shares Rise 12% After Tubeless Mobi Clearance
Tandem said the U.S. Food and Drug Administration granted 510(k) clearance for the tubeless system. Shares reached $19.62 at 9:59 a.m. ET.
More news
- TokenPostShell Buys 2 Million Shares Under Its $5 Billion Buyback Program
- TokenPostCintas-UniFirst Deal Spread Reaches $97 for Planned Purchase
- TokenPostSeven U.S. Stock Tickers Fall at Least 10.3% in 24 Hours
- The DefiantBitcoin Heads for Sixth Weekly Loss, Down 22% in 2026
- Crypto BriefingNvidia CEO Jensen Huang resigns, Colette Kress named interim chief
- TokenPostPAVmed Advances Veris Implantable Monitor Toward Early 2027 FDA Filing